Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of Cure

The IMS and IMWG issued a new consensus definition of cure for multiple myeloma, requiring five years of complete remission with at least four negative MRD tests using next-generation sequencing or next-generation flow at 10^-6 sensitivity. clonoSEQ, Adaptive's FDA-cleared NGS MRD test, is explicitly positioned to play a central role under the definition, and its chief commercial officer tied the milestone to last week's NCCN Guidelines update supporting routine MRD integration. The definition creates a structural demand tailwind for high-sensitivity MRD testing in myeloma, though the release does not quantify near-term revenue impact.

•1mo ago

Adaptive Biotechnologies Announces Update to NCCN Guidelines® for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ®

The NCCN updated its Clinical Practice Guidelines for Multiple Myeloma to add a dedicated MRD testing framework on a new page, MYEL-E, establishing routine minimal residual disease assessment across the myeloma patient journey for the first time. Bone marrow-based MRD assessment is now recommended using next-generation sequencing with an FDA-approved assay — clonoSEQ is the only assay specifically named in the guidelines — and 10^-6 sensitivity is stated as preferred, with 10^-5 the minimum. Recommended MRD timepoints were expanded to include annual testing during maintenance and assessment after later lines of therapy, including after CAR T-cell therapy, reinforcing MRD as a longitudinal measure that can guide treatment escalation, de-escalation, and discontinuation. Adaptive's Chief Commercial Officer for MRD, Susan Bobulsky, said the updates underscore clonoSEQ's established leadership in hematology MRD testing; the release does not quantify the expected commercial or reimbursement impact.

•1mo ago

Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results

Adaptive Biotechnologies reported Q2 revenue of $71.6 million, up 22% year-over-year, driven by a 33% increase in its Minimal Residual Disease (MRD) segment which now accounts for 92% of total sales. Adjusted EBITDA improved to a loss of $0.7 million from a loss of $7.2 million in the prior year, reflecting expanding profitability as the core business scales and operating expenses remain controlled. The company raised full-year MRD guidance to $268 million-$278 million and announced plans to separate its MRD and Immune Medicine businesses, supported by a strengthened balance sheet with $371.7 million in cash and securities following a recent debt offering.

•3mo ago

Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering

Adaptive Biotechnologies priced an upsized $300 million offering of 0% convertible senior notes due 2031, increasing from a previously announced $250 million. Net proceeds are expected to total approximately $290.8 million, with the company planning to use funds to repay the OrbiMed Purchase Agreement and support MRD business initiatives. To mitigate potential dilution, the firm will enter into capped call transactions and repurchase $25 million of its common stock concurrently with the offering.

•4mo ago

At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ® MRD Testing Across Hematology Clinical Practice and Research

Adaptive Biotechnologies announced that its clonoSEQ MRD test will be featured in 33 presentations at the ASCO and EHA 2026 conferences, including 14 oral presentations and one plenary session. The data presented reinforces clonoSEQ’s position as the gold standard for measurable residual disease assessment across multiple hematologic malignancies, including multiple myeloma, CLL, and lymphoma. Management highlighted that the breadth of presentations reflects the maturation of the MRD field and the increasing incorporation of MRD-guided care into clinical practice and drug development.

•5mo ago

Adaptive Biotechnologies Reports First Quarter 2026 Financial Results

Adaptive Biotechnologies reported Q1 2026 revenue of $70.9 million, a 35% year-over-year increase, driven primarily by a 53% jump in MRD revenue to $67.1 million. clonoSEQ test volume rose 41% to 32,595 tests, and the company recognized a $9.0 million regulatory milestone, its first U.S. primary endpoint milestone. Management raised full-year 2026 MRD revenue guidance to $260 million-$270 million, up from the prior range of $255 million-$265 million.

•5mo ago